Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO

Written by: Nola Cadman
Published On: 6 Aug 2020

Oxford, UK and Helsinki, Finland, 3rd August 2020: Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing targeted therapeutics using tumor antigen-coated oncolytic viruses, today announced it had appointed industry veteran Paul G Higham as Chief Executive Officer (CEO), to lead the company through a Series A round and take its PeptiCRAd platform into first-in-human cancer clinical trials. 

Matti Hautsalo, Chairman of the Board, said, “I am delighted to welcome Paul to the Company. His wealth of experience in leading immuno-oncology companies means he is the perfect fit for Valo. I would like to thank Michael Stein for his excellent work, the smooth handover of the CEO role to Paul, and for providing the company with a strong foundation to progress its PeptiCRAd technology into the clinic.”

Paul G Higham, CEO of Valo Tx, said, “Despite the tremendous progress that has been made, there is still huge potential for immuno-oncology to further improve outcomes for patients. I am delighted to join Valo, and to apply my experience to move the exciting technology the company has created into the clinic. We want, and expect, to be able to significantly improve the prospects for patients across a broad range of cancer types.” 

Dr Michael Stein, outgoing CEO of Valo Tx, commented, “It has been a great experience to lead Valo to this stage and to help create the company’s PeptiCRAd platform to develop tumor antigen-coated oncolytic viruses as therapeutics. I thank the exceptional team for all their hard work and look forward to continuing my role on the Board of Directors.”

Paul G Higham brings over 15-years C-Suite biotech experience, including previously as CEO of two immuno-oncology companies, Germany’s Glycotope, and Immatics Biotechnologies (NASDAQ: IMTX). His CEO experience is built on a strong foundation of strategic and operational roles including Director of Commercial Development at Ark Therapeutics Group, where he established the company’s adenovirus gene-based medicine production facilities in Finland, as VP Commercial Development at GSK, and as General Manager of Bayer Pharmaceuticals for Sweden and Denmark.